Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy

NCT00498368 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

IgA Nephropathy

Interventions

DRUG: Intravenous Rituximab
DRUG: ACE/ARB
DIETARY_SUPPLEMENT: Omega-3 Fatty Acid Fish Oil Supplement

Sponsor

Mayo Clinic

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]